The pharmacokinetic profile of recombinant human erythropoietin is unchanged in patients undergoing cardiac surgery
| Autor: | Ludwik Fedorko, Wing K. Cheung, Bobby Mehta, George Djaiani, Stuart A. McCluskey, Humara Poonawala, Keyvan Karkouti, Rita Katznelson |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
medicine.medical_specialty Metabolic Clearance Rate Coronary Artery Bypass Off-Pump Blood volume Placebo law.invention Pharmacokinetics law medicine Cardiopulmonary bypass Humans Pharmacology (medical) Prospective Studies Erythropoietin Aged Pharmacology Volume of distribution Cardiopulmonary Bypass business.industry General Medicine Middle Aged Recombinant Proteins Cardiac surgery medicine.anatomical_structure Area Under Curve Anesthesia Injections Intravenous Female business Half-Life medicine.drug Artery |
| Zdroj: | European Journal of Clinical Pharmacology. 65:273-279 |
| ISSN: | 1432-1041 0031-6970 |
| Popis: | In anticipation of future studies, we examined the pharmacokinetics profile of erythropoietin (EPO) in patients undergoing cardiac surgery.Cardiac surgical patients were enrolled into one of six groups: four cardiopulmonary bypass (CPB) groups [placebo (n = 6), 250 IU/kg EPO (n = 3), 500 IU/kg EPO (n = 3), and 500 IU/kg EPO, two doses (n = 6)] and two off-pump coronary artery bypass (OPCAB) groups [placebo (n = 3) and 500 IU/kg EPO (n = 3)]. The EPO was administered prior to anesthesia and 10 min after CPB (if required). Blood samples for serum EPO were collected at baseline, 10 min after dosing, 5 min after sternotomy, during CPB or the equivalent for OPCAB (5, 15, 45, 60 min), and post-CPB (5, 15, 45, and 60 min, 6, 12 and 24 h, and daily until day 5).Endogenous EPO increased within 24 h of surgery in the placebo group and remained elevated. There was approximately a 40% decrease in serum EPO concentration at the initiation of CPB due to an increase in circulatory blood volume. There were no differences in apparent volume of distribution in the plasma (Vc) (42.2 +/- 9.9, 39.8 +/- 6.3, 42.3 +/- 14.0 mL/kg), clearance (CL) (4.63 +/- 1.14, 3.44 +/- 0.68, 4.27 +/- 0.52 mL h/kg), and t((1/2)) (16.4 +/- 8.0 16.9 +/- 10.6, 22.4 +/- 9.3 h) between the CPB treatment groups. The pharmacokinetic profile of EPO in the OPCAB group was similar to that for the CPB groups: Vc = 39.3 +/- 7.0 mL/kg, CL = 4.98 +/- 0.17 mL h/kg and t((1/2)) = 17.1 +/- 18.1 h.CPB had no apparent effect on the pharmacokinetics of EPO. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink